Pawan Kumar

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels
    Bhavna Kumar
    Department of Otolaryngology Head and Neck Surgery, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Mol Cancer Ther 11:1988-98. 2012
  2. ncbi Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis
    Pawan Kumar
    Department of Otolaryngology Head and Neck Surgery and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Mol Cancer 9:206. 2010
  3. ncbi Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins
    Arti Yadav
    The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Mol Cancer Ther 10:1241-51. 2011
  4. ncbi IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway
    Arti Yadav
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Mol Cancer Res 9:1658-67. 2011
  5. ncbi Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis
    Bhavna Kumar
    Department of Otolaryngology Head and Neck Surgery, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 7:e37601. 2012
  6. ncbi MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib
    Shoumei Bai
    Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 284:32015-27. 2009
  7. ncbi RhoC expression and head and neck cancer metastasis
    Mozaffarul Islam
    Department of Otolaryngology Head and Neck Surgery, Ohio State University, Columbus, OH 43210, USA
    Mol Cancer Res 7:1771-80. 2009

Collaborators

Detail Information

Publications7

  1. ncbi YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels
    Bhavna Kumar
    Department of Otolaryngology Head and Neck Surgery, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Mol Cancer Ther 11:1988-98. 2012
    ..Taken together, our results suggest a potentially novel strategy to use YM155 to overcome the resistance in tumor cells, thereby enhancing the effectiveness of the chemotherapy in HNSCC...
  2. ncbi Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis
    Pawan Kumar
    Department of Otolaryngology Head and Neck Surgery and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Mol Cancer 9:206. 2010
    ..However, very little is known about the effect of TM on tumor cell function and tumor metastasis. In this study, we explored the mechanisms underlying TM-mediated inhibition of tumor metastasis...
  3. ncbi Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins
    Arti Yadav
    The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Mol Cancer Ther 10:1241-51. 2011
    ..Taken together, our results suggest a potentially novel strategy to use sorafenib to overcome chemo- and radioresistance in tumor and tumor-associated endothelial to enhance the effectiveness of the chemoradiation therapy...
  4. ncbi IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway
    Arti Yadav
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Mol Cancer Res 9:1658-67. 2011
    ..Taken together, these results show a novel function for IL-6 in mediating EMT in head and neck tumor cells and increasing their metastatic potential...
  5. ncbi Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis
    Bhavna Kumar
    Department of Otolaryngology Head and Neck Surgery, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 7:e37601. 2012
    ..miR-34a is a tumor-suppressor that is frequently downregulated in a number of tumor types. However, little is known about the role of miR-34a in head and neck squamous cell carcinoma (HNSCC)...
  6. ncbi MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib
    Shoumei Bai
    Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 284:32015-27. 2009
    ....
  7. ncbi RhoC expression and head and neck cancer metastasis
    Mozaffarul Islam
    Department of Otolaryngology Head and Neck Surgery, Ohio State University, Columbus, OH 43210, USA
    Mol Cancer Res 7:1771-80. 2009
    ..These findings suggest that RhoC warrants further investigation to delineate its robustness as a novel potentially therapeutic target...